The U.S. Food and Drug Administration has approved Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF).
This article was originally published on MedicalXpress.com
FDA approves Jascayd for idiopathic pulmonary fibrosis
You may also be interested in:
The Latest
5 Popular Supplements in Canada for Optimal Health and Wellness
As a health and wellness enthusiast, I have always been interested in the role of supplements in promoting optimal health. In Canada, there are many supplements available on the market, each with different benefits and […]
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
The Latest
Setting Boundaries: Nurturing a Healthy Partnership
What Are Boundaries? As the word portrays, boundaries in a relationship help each person establish expectations with their partner. Boundaries can help you communicate what you are comfortable with and what you are willing to […]
Read More:
-
Children living near the Salton Sea, in Southern California’s desert region of Imperial County, are experiencing poorer lung function than children exposed to less wind-blown [...]
-
The earlier teenagers begin drinking before the minimum legal age for purchasing alcohol, the higher the risk of heavy drinking and alcohol-related harms in early [...]
-
The NHS incurs an estimated £340 million in additional health care costs annually due to weight-related health problems in children—but it is not just obesity [...]
